Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for prevention of contrast-induced nephropathy in patients undergoing angioplasty
IRCT20190406043182N1Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of allopurinol in contrast-induced nephropathy (CIN), sponsored by Tabriz University of Medical Sciences. Started Apr 2019; status: completed.
02
Drugs
allopurinol
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20190406043182N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190406043182N1.